{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:15:16Z","timestamp":1794600916998,"version":"4.9.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Pulmonary sarcomatoid carcinoma (PSC) is an uncommon type of non-small cell lung cancer, exhibiting aggressive behavior and resistance to the conventional chemoradiotherapy. To date, the optimal treatment for PSC has not been elucidated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>Three male patients including a 69-year-old smoker (Case 1), a 45-year-old non-smoker (Case 2), and a 69-year-old smoker (Case 3) were admitted because of cough, back pain, and loss of body weight respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Radiographical examinations in these patients showed bulky intrathoracic lesions, which were pathologically diagnosed as PSC staging III\u2013IV by computed tomography\u2013guided percutaneous biopsy and endoscopy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Immunotherapy was not covered by their health insurance and they refused immune checkpoint inhibitors for financial reasons. In addition, a radical resection was not appropriate due to the advanced staging of these lesions. Therefore, first-line albumin-bound paclitaxel (nab-paclitaxel, 260\u200amg\/m<jats:sup>2<\/jats:sup> of the body surface area) and carboplatin (area under curve 5) combined with oral apatinib (425\u200amg, daily) were administered empirically.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Two patients achieved a partial response and the other case showed stable disease lasting for more than 6 months. However, 1 of them indicated progression on the 7-month follow up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Nab-paclitaxel\/carboplatin plus apatinib showed limited short-term efficacy in advanced, unresectable PSC. The rapid resistance of PSC to the current therapeutic regimen necessitates further researches, as more effective agents are urgently needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020667","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T20:04:55Z","timestamp":1591214695000},"page":"e20667","source":"Crossref","is-referenced-by-count":9,"title":["First-line albumin-bound paclitaxel\/carboplatin plus apatinib in advanced pulmonary sarcomatoid carcinoma"],"prefix":"10.1097","volume":"99","author":[{"given":"Feng-Wei","family":"Kong","sequence":"first","affiliation":[{"name":"Department of General Surgery, Xuzhou Infectious Disease Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Min","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Xuzhou Infectious Disease Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yichang Central People's Hospital, Institute of Digestive Disease, China Three Gorges University, Yichang"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Bin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Xuzhou Central Hospital, Xuzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Xuzhou Central Hospital, Xuzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7431-5986","authenticated-orcid":false,"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Surgery, Xuzhou Central Hospital, Xuzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0221-7","article-title":"Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety","volume":"51","author":"Liao","year":"2019","journal-title":"Exp Mol Med"},{"key":"R2-20230915","first-page":"e12083:1\u201312","article-title":"Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: a pooled analysis","volume":"97","author":"Ma","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/PAS.0000000000001268","article-title":"The prognostic significance of the 8th edition TNM staging of pulmonary carcinoid tumors: a single institution study with long-term follow-up","volume":"43","author":"Dermawan","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cllc.2016.11.016","article-title":"Pulmonary sarcomatoid carcinoma: an analysis of the national cancer data base","volume":"18","author":"Steuer","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7819-11-252","article-title":"Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases","volume":"11","author":"Huang","year":"2013","journal-title":"World J Surg Oncol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.lungcan.2014.06.004","article-title":"Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung","volume":"85","author":"Vieira","year":"2014","journal-title":"Lung Cancer"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.biopha.2015.10.009","article-title":"Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma","volume":"76","author":"Gu","year":"2015","journal-title":"Biomed Pharmacother"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/COC.0000000000000101","article-title":"Characteristics and prognostic analysis of 69 patients with pulmonary sarcomatoid carcinoma","volume":"39","author":"Lin","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cllc.2016.03.001","article-title":"Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung","volume":"17","author":"Ung","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"R10-20230915","first-page":"407","article-title":"Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages","volume":"24","author":"Roesel","year":"2017","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10238-018-0517-2","article-title":"A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung","volume":"18","author":"Hou","year":"2018","journal-title":"Clin Exp Med"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/j.cllc.2017.12.008","article-title":"Sarcomatoid carcinoma of the lung: the Mayo Clinic experience in 127 patients","volume":"19","author":"Maneenil","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.18632\/oncotarget.23468","article-title":"Pulmonary sarcomatoid carcinoma: University of Cincinnati experience","volume":"9","author":"Karim","year":"2018","journal-title":"Oncotarget"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3904\/kjim.2017.245","article-title":"Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma","volume":"33","author":"Sim","year":"2018","journal-title":"Korean J Intern Med"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"819","DOI":"10.21037\/jtd.2019.02.02","article-title":"Perioperative change in neutrophil-to-lymphocyte ratio (NLR) is a prognostic factor in patients with completely resected primary pulmonary sarcomatoid carcinoma","volume":"11","author":"Seong","year":"2019","journal-title":"J Thorac Dis"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/ejcts\/ezx417","article-title":"Pulmonary sarcomatoid carcinoma: an analysis of a rare cancer from the surveillance, epidemiology, and end results database","volume":"53","author":"Rahouma","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.athoracsur.2016.08.114","article-title":"Pathologic findings and long-term results after surgical treatment for pulmonary sarcomatoid tumors: a multicenter analysis","volume":"103","author":"Lococo","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/01.JTO.0000437008.00554.90","article-title":"Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma","volume":"8","author":"Vieira","year":"2013","journal-title":"J Thorac Oncol"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.ejca.2015.08.013","article-title":"Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas","volume":"51","author":"Kim","year":"2015","journal-title":"Eur J Cancer"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/PAP.0000000000000202","article-title":"Pulmonary sarcomatoid carcinomas: a review","volume":"25","author":"Weissferdt","year":"2018","journal-title":"Adv Anat Pathol"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2016.05.013","article-title":"Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages","volume":"98","author":"Vieira","year":"2016","journal-title":"Lung Cancer"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000492666","article-title":"Nivolumab-induced impressive response of refractory pulmonary sarcomatoid carcinoma with brain metastasis","volume":"11","author":"Salati","year":"2018","journal-title":"Case Rep Oncol"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1016\/j.cllc.2018.12.013","article-title":"Immune checkpoint blockade is associated with durable responses in pulmonary sarcomatoid carcinoma","volume":"20","author":"Sukrithan","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"R24-20230915","first-page":"310","article-title":"Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review","volume":"26","author":"Kotlowska","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.3747\/co.26.4377","article-title":"Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung","volume":"26","author":"Roesel","year":"2019","journal-title":"Curr Oncol"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jtho.2016.01.009","article-title":"Synergistic activation upon met and alk coamplification sustains targeted therapy in sarcomatoid carcinoma, a deadly subtype of lung cancer","volume":"11","author":"Pelosi","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1586\/17476348.2016.1157475","article-title":"Recent advances in the management of pulmonary sarcomatoid carcinoma","volume":"10","author":"Shum","year":"2016","journal-title":"Expert Rev Respir Med"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jtho.2017.03.005","article-title":"Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling","volume":"12","author":"Schrock","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-18-2364","article-title":"An epithelial-to-mesenchymal transcriptional switch triggers evolution of pulmonary sarcomatoid carcinoma (PSC) and identifies dasatinib as new therapeutic option","volume":"25","author":"Manzotti","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/his.13505","article-title":"KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma","volume":"73","author":"Mehrad","year":"2018","journal-title":"Histopathology"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jtho.2016.04.020","article-title":"Deep sequencing analysis reveals that kras mutation is a marker of poor prognosis in patients with pulmonary sarcomatoid carcinoma","volume":"11","author":"Lococo","year":"2016","journal-title":"J Thorac Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:08:09Z","timestamp":1694822889000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020667"}},"subtitle":["A case series and review of the literature"],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":31,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020667","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]}}}